[144] Akero Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Akero Therapeutics (AKRO) Form 144 filing reports a proposed sale of Common Stock by an insider. The notice lists a broker, J.P. Morgan Securities, and an approximate aggregate market value of the proposed sale at $4,015,800 for 90,000 shares, with an approximate sale date of 09/10/2025 on NASDAQ. The filing details the insider's acquisition history: 478 shares from an ESPP on 06/28/2024, 14,581 shares from RSU vesting on 03/09/2023, and 74,941 shares from a stock option exercise on 09/10/2025. It also discloses recent dispositions: 30,000 shares sold on 07/10/2025 for $1,534,895 and 30,000 shares sold on 08/11/2025 for $1,457,589. The filer represents no undisclosed material adverse information.

Insights

Securities Analyst

TL;DR: Insider intends to sell 90,000 AKRO shares (~$4.0M); recent sales of 60,000 shares generated ~$3.0M in proceeds.

The filing is a routine Rule 144 notice from a person tied to Akero Therapeutics reporting planned sale through J.P. Morgan Securities. The filing quantifies holdings acquired via ESPP, RSU vesting and option exercise, and lists two recent open-market sales totaling 60,000 shares. This is a disclosure of planned insider liquidity rather than corporate action; it provides clear transaction dates, acquisition methods and gross proceeds, enabling investors to track insider selling activity.

Corporate Governance Expert

TL;DR: Disclosure meets Rule 144 requirements; sale is an insider liquidity event, not a corporate development.

The notice documents that the securities to be sold were largely acquired through compensation programs (ESPP and RSUs) and an option exercise, and it includes a broker and an intended sale date. The signer certifies no undisclosed material adverse information. From a governance perspective, timely disclosure of insider sales preserves regulatory transparency; the filing contains no information about changes in management or corporate policies.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	J.P. Morgan Securities LLC 390 Madison Avenue, 6th Floor New York NY 10017	90000	4015800	79988975	09/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	06/28/2024	ESPP	Issuer			478	06/28/2024	Cash
Common Stock	03/09/2023	RSU Vesting	Issuer			14581	06/08/2024	Compensation
Common Stock	09/10/2025	Stock Option Exercise	Issuer			74941	09/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Andrew Cheng C/o Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	Common Stock	07/10/2025	30000	1534895
Andrew Cheng C/o Akero Therapeutics, Inc. 601 Gateway Boulevard, Suite 350 South San Francisco CA 94080	Common Stock	08/11/2025	30000	1457589

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the AKRO Form 144 report?

The filing reports a proposed sale of 90,000 AKRO common shares via J.P. Morgan with an aggregate market value of $4,015,800, dated 09/10/2025.

Who is selling the shares reported in the AKRO Form 144?

The seller named is Andrew Cheng (address listed c/o Akero Therapeutics, Inc.); the filing shows prior sales and acquisition details for the securities.

What were the recent insider sales before this filing?

Two prior sales are disclosed: 30,000 shares sold on 07/10/2025 for $1,534,895 and 30,000 shares sold on 08/11/2025 for $1,457,589.

How were the shares being sold originally acquired?

Acquisitions shown include an ESPP purchase (06/28/2024, 478 shares), RSU vesting (03/09/2023, 14,581 shares), and a stock option exercise (09/10/2025, 74,941 shares).

Will this Form 144 tell me if the company authorized the sale?

No. The Form 144 discloses the seller's proposed sale and representations; it does not indicate corporate approval or effect on company operations.